VICP
Vicapsys Life Sciences, Inc.
Price Chart
Latest Quote
$1.46
+0.00 (+0.00%)
Current Price
| Previous Close | $1.46 |
| Open | $0.51 |
| Day High | $0.51 |
| Day Low | $0.51 |
| Volume | 100 |
Stock Information
| Shares Outstanding | 32.37M |
| Total Debt | $579K |
| Cash Equivalents | $90K |
| Net Income | $-1.35M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $47.26M |
| EPS (TTM) | $-0.03 |
| Exchange | PNK |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $47.75M |
| Income | $-1.35M |
| Book/sh | $-0.08 |
| Cash/sh | $0.00 |
| Employees | 2 |
Financial Ratios
| Quick Ratio | 0.03 |
| Current Ratio | 0.03 |
Returns & Margins
| ROA | -466.43% |
Ownership
| Insider Ownership | 18.75% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/B | -17.80 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $1.46 |
| SMA50 | $1.41 |
| SMA200 | $1.54 |
| RSI | nan |
| Shares Float | 18.41M |
| Volatility | 417511.16 |
Performance History
| Week | +0.00% |
| Month | +0.00% |
| Quarter | -2.67% |
| 6 Months | -2.67% |
| YTD | -2.67% |
| Year | -17.51% |
| 3 Years | +46.00% |
| 5 Years | +31.53% |
| 10 Years | -27.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-03 | $1.46 | 0 |
| 2026-06-02 | $1.46 | 0 |
| 2026-06-01 | $1.46 | 0 |
| 2026-05-29 | $1.46 | 0 |
| 2026-05-28 | $1.46 | 0 |
| 2026-05-27 | $1.46 | 0 |
| 2026-05-26 | $1.46 | 0 |
| 2026-05-22 | $1.46 | 0 |
| 2026-05-21 | $1.46 | 0 |
| 2026-05-20 | $1.46 | 0 |
| 2026-05-19 | $1.46 | 0 |
| 2026-05-18 | $1.46 | 0 |
| 2026-05-15 | $1.46 | 0 |
| 2026-05-14 | $1.46 | 0 |
| 2026-05-13 | $1.46 | 0 |
| 2026-05-12 | $1.46 | 0 |
| 2026-05-11 | $1.46 | 0 |
| 2026-05-08 | $1.46 | 0 |
| 2026-05-07 | $1.46 | 0 |
| 2026-05-06 | $1.46 | 0 |
| 2026-05-05 | $1.46 | 0 |
| 2026-05-04 | $1.46 | 0 |
About Vicapsys Life Sciences, Inc.
Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company's product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics International, Inc. and changed its name to Vicapsys Life Sciences, Inc. in September 2017. Vicapsys Life Sciences, Inc. was incorporated in 1997 and is based in Suwanee, Georgia.
đ° Latest News
No news articles available at the moment. Check back later for updates on VICP.
Period:
Loading...
Income Statement (Annual)
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
| Expenses | |||
| Interest Expense | $19,969 | $0 | - |
| Total Expenses | $1,046,978 | $644,559 | $336,871 |
| Net Non Operating Interest Income Expense | $-135,134 | $0 | - |
| Total Other Finance Cost | $115,165 | - | - |
| Interest Expense Non Operating | $19,969 | $0 | - |
| Operating Expense | $1,046,978 | $644,559 | $336,871 |
| General And Administrative Expense | $1,031,711 | $631,462 | $319,173 |
| Other Income Expense | - | $-340,231 | $100,000 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-1,182,112 | $-984,790 | $-236,871 |
| Net Interest Income | $-135,134 | $0 | - |
| Normalized Income | $-1,182,112 | $-644,559 | $-336,871 |
| Net Income From Continuing And Discontinued Operation | $-1,182,112 | $-984,790 | $-236,871 |
| Total Operating Income As Reported | $-1,046,978 | $-984,790 | $-336,871 |
| Net Income Common Stockholders | $-1,182,112 | $-988,338 | $-236,871 |
| Net Income | $-1,182,112 | $-984,790 | $-236,871 |
| Net Income Including Noncontrolling Interests | $-1,182,112 | $-984,790 | $-236,871 |
| Net Income Continuous Operations | $-1,182,112 | $-984,790 | $-236,871 |
| Pretax Income | $-1,182,112 | $-984,790 | $-236,871 |
| Special Income Charges | $0 | $-340,231 | $100,000 |
| Operating Income | $-1,046,978 | $-644,559 | $-336,871 |
| Per Share | |||
| Diluted EPS | $-0.03 | $-0.03 | $-0.01 |
| Basic EPS | $-0.03 | $-0.03 | $-0.01 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-1,162,143 | $-613,270 | $-405,542 |
| Total Unusual Items | $0 | $-340,231 | $100,000 |
| Total Unusual Items Excluding Goodwill | $0 | $-340,231 | $100,000 |
| Reconciled Depreciation | $0 | $31,289 | $31,329 |
| EBITDA (Bullshit earnings) | $-1,162,143 | $-953,501 | $-305,542 |
| EBIT | $-1,162,143 | $-984,790 | $-336,871 |
| Diluted Average Shares | $34,548,676 | $30,577,988 | $17,656,762 |
| Basic Average Shares | $34,548,676 | $30,577,988 | $17,656,762 |
| Diluted NI Availto Com Stockholders | $-1,182,112 | $-988,338 | $-236,871 |
| Otherunder Preferred Stock Dividend | $0 | $3,548 | $0 |
| Tax Provision | $0 | $0 | $0 |
| Write Off | $0 | $340,231 | $0 |
| Research And Development | $15,267 | $13,097 | $17,698 |
| Selling General And Administration | $1,031,711 | $631,462 | $319,173 |
| Other Gand A | $769,086 | $509,004 | $227,671 |
| Salaries And Wages | $262,625 | $122,458 | $91,502 |
| Gain On Sale Of Business | - | - | $100,000 |
Fetched: 2026-02-02
Balance Sheet (Annual)
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-1,928,681 | $-950,791 | $-493,171 |
| Total Assets | $39,656 | $72,021 | $594,313 |
| Total Non Current Assets | $0 | $0 | $371,520 |
| Current Assets | $39,656 | $72,021 | $222,793 |
| Current Deferred Assets | $0 | $50,441 | $0 |
| Prepaid Assets | $30,234 | $7,483 | $5,498 |
| Cash Cash Equivalents And Short Term Investments | $9,422 | $14,097 | $217,295 |
| Cash And Cash Equivalents | $9,422 | $14,097 | $217,295 |
| Cash Financial | $9,422 | $14,097 | $217,295 |
| Goodwill And Other Intangible Assets | - | $0 | $371,520 |
| Other Intangible Assets | - | - | $371,520 |
| Debt | |||
| Net Debt | $344,446 | - | - |
| Total Debt | $353,868 | - | - |
| Current Debt And Capital Lease Obligation | $353,868 | - | - |
| Current Debt | $353,868 | - | - |
| Other Current Borrowings | $335,156 | - | - |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $1,968,337 | $1,022,812 | $715,964 |
| Total Non Current Liabilities Net Minority Interest | $0 | $0 | $0 |
| Current Liabilities | $1,968,337 | $1,022,812 | $715,964 |
| Current Notes Payable | $18,712 | $0 | - |
| Payables And Accrued Expenses | $1,614,469 | $1,022,812 | $715,964 |
| Payables | $1,499,157 | $907,500 | $600,652 |
| Accounts Payable | $1,499,157 | $907,500 | $600,652 |
| Equity | |||
| Common Stock Equity | $-1,928,681 | $-950,791 | $-121,651 |
| Total Equity Gross Minority Interest | $-1,928,681 | $-950,791 | $-121,651 |
| Stockholders Equity | $-1,928,681 | $-950,791 | $-121,651 |
| Retained Earnings | $-16,300,075 | $-15,117,963 | $-14,129,625 |
| Other Equity Interest | - | $727 | $12,068 |
| Other | |||
| Ordinary Shares Number | $32,071,299 | $31,188,461 | $19,747,283 |
| Share Issued | $32,071,299 | $31,188,461 | $19,747,283 |
| Tangible Book Value | $-1,928,681 | $-950,791 | $-493,171 |
| Invested Capital | $-1,574,813 | $-950,791 | $-121,651 |
| Working Capital | $-1,928,681 | $-950,791 | $-493,171 |
| Total Capitalization | $-1,928,681 | $-950,791 | $-121,651 |
| Additional Paid In Capital | $14,339,323 | $14,135,257 | $13,976,159 |
| Capital Stock | $32,071 | $31,188 | $19,747 |
| Common Stock | $32,071 | $31,188 | $19,747 |
| Preferred Stock | $0 | $0 | $0 |
| Current Accrued Expenses | $115,312 | $115,312 | $115,312 |
Fetched: 2026-02-02
Cash Flow Statement (Annual)
| Metric | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-417,524 | $-238,197 | $-443,974 |
| Operating Activities | |||
| Operating Cash Flow | $-417,524 | $-238,197 | $-443,974 |
| Cash Flow From Continuing Operating Activities | $-417,524 | $-238,197 | $-443,974 |
| Operating Gains Losses | - | - | $-100,000 |
| Investing Activities | |||
| Investing Cash Flow | - | $0 | $100,000 |
| Cash Flow From Continuing Investing Activities | - | $0 | $100,000 |
| Financing Activities | |||
| Issuance Of Capital Stock | $100,000 | $0 | $560,000 |
| Financing Cash Flow | $412,849 | $34,999 | $560,000 |
| Cash Flow From Continuing Financing Activities | $412,849 | $34,999 | $560,000 |
| Net Other Financing Charges | $50,441 | $-15,001 | - |
| Net Common Stock Issuance | $100,000 | $0 | $560,000 |
| Common Stock Issuance | $100,000 | $0 | $560,000 |
| Other | |||
| Repayment Of Debt | $-41,192 | $0 | - |
| Issuance Of Debt | $303,600 | $0 | - |
| Interest Paid Supplemental Data | $19,969 | $0 | $0 |
| Income Tax Paid Supplemental Data | $545 | $0 | $0 |
| End Cash Position | $9,422 | $14,097 | $217,295 |
| Beginning Cash Position | $14,097 | $217,295 | $1,269 |
| Changes In Cash | $-4,675 | $-203,198 | $216,026 |
| Proceeds From Stock Option Exercised | $0 | $50,000 | $0 |
| Net Issuance Payments Of Debt | $262,408 | $0 | - |
| Net Short Term Debt Issuance | $262,408 | $0 | - |
| Short Term Debt Payments | $-41,192 | $0 | - |
| Short Term Debt Issuance | $303,600 | $0 | - |
| Change In Working Capital | $628,809 | $269,423 | $-142,758 |
| Change In Payables And Accrued Expense | $591,657 | $271,408 | $-137,260 |
| Change In Payable | $591,657 | $271,408 | $-137,260 |
| Change In Account Payable | $591,657 | $271,408 | $-137,260 |
| Change In Prepaid Assets | $37,152 | $-1,985 | $-5,498 |
| Other Non Cash Items | $115,082 | - | - |
| Stock Based Compensation | $20,697 | $105,650 | $4,326 |
| Asset Impairment Charge | $0 | $340,231 | $0 |
| Depreciation Amortization Depletion | $0 | $31,289 | $31,329 |
| Depreciation And Amortization | $0 | $31,289 | $31,329 |
| Amortization Cash Flow | $0 | $31,289 | $31,329 |
| Amortization Of Intangibles | $0 | $31,289 | $31,329 |
| Net Income From Continuing Operations | $-1,182,112 | $-984,790 | $-236,871 |
| Net Business Purchase And Sale | - | $0 | $100,000 |
| Sale Of Business | - | $0 | $100,000 |
| Gain Loss On Sale Of Business | - | $0 | $-100,000 |
Fetched: 2026-02-02